/
.webp)
Generated by Master Biographer | Source for LinkedIn Content
It's 2005. Peter Gassner walks out of Salesforce's San Francisco headquarters for the last time.
He'd spent two years there as Senior Vice President of Technology. He helped build the platform. He helped design the AppExchange — the app marketplace that let other developers build on top of Salesforce's infrastructure. He was one of the architects of the very thing that was making Salesforce the fastest-growing enterprise software company in history.
And now he was leaving.
Not to build the next horizontal CRM. Not to take on Salesforce head-on with a better product for everyone. His bet was smaller. Stranger. More specific.
He was going to build a CRM for one industry only: pharmaceutical.
Everyone thought he was limiting himself. He thought they were wrong about what a limit is.
Gassner is not a typical Silicon Valley founder. He started at IBM in the early 1990s, working on relational databases. Then PeopleSoft, where he rose to Chief Architect and General Manager of the PeopleTools division — running a 450-person engineering team. Then Salesforce, joining in 2003 just before its IPO.
He was 42 years old when he founded Veeva. A late bloomer by startup standards. He'd spent two decades deep inside enterprise software — relational databases, HR platforms, CRM infrastructure. He'd seen what made these platforms powerful. And he'd seen where they broke.
After leaving Salesforce in 2005, he took time to think. The question he kept returning to: what comes after horizontal?
Salesforce had proven that software could work in the cloud. But Salesforce was built for everyone — which meant it was optimized for no one in particular. A one-size-fits-all product in an economy where every industry operates differently.
Gassner's thesis: "The next wave after horizontal solutions like Accounting and Payroll would be something specific to an industry."
He was describing what would later be called "vertical SaaS." In 2006, that phrase didn't exist. The concept barely existed. Most people in enterprise software thought you needed to be horizontal to have a large enough market to matter.
Gassner thought that was exactly backwards.
Gassner teamed up with Matt Wallach — a former Siebel Systems executive who brought something Gassner didn't have: direct relationships inside pharmaceutical sales organizations. They had never met and lived 3,000 miles apart. They connected over a shared belief that cloud computing was going to do to pharma what it had done to every other industry — and that nobody was building for pharma specifically.
The insight was regulatory.
Pharma CRM isn't CRM in the generic sense. When a pharmaceutical sales rep visits a doctor — an act called "detailing" — every single interaction has to be logged with compliance-specific data. Not just name, date, notes. Federal law mandates it.
Under the Sunshine Act (the Physician Payments Sunshine Act, part of the Affordable Care Act), pharmaceutical companies must track every dollar of value transferred to a healthcare provider — every meal, every sample, every educational event — and report it to the federal government annually. The Department of Health and Human Services publishes it all in a public database. A free lunch for a doctor at a sales presentation? Logged. The cost split among the physicians in the room? Calculated and attributed.
This compliance layer doesn't exist in generic CRM. Salesforce was not built to track aggregate physician spend across thousands of field reps in real time, flag when a doctor is approaching a spend limit, block a rep from promoting off-label uses, or generate regulatory submissions in FDA-compliant formats.
Generic Salesforce could theoretically be customized to do all of this. But "could theoretically be customized" is not the same as "built for it from the ground up." The customization costs — in money, in failed implementations, in compliance risk — were enormous.
Gassner saw that pharma companies were paying a premium to make a horizontal tool do a vertical job, and doing it badly. The opening was enormous. And because the switching costs would be high for a purpose-built product, anyone who captured the market first would be very hard to displace.
He went to four potential customers with his first product concept. All four said it was a bad idea.
This was not the defeat it sounds like. Gassner's method: "You have to listen to what they feel, not what they say. Are they emotionally attached to where they're getting their product now? I could tell in their responses that they weren't attached and they weren't getting value."
They were saying no. Their emotional detachment from their existing tools was saying yes.
The company was not called Veeva when it launched. It was called Verticals onDemand, Inc. — registered in January 2007. The name was renamed to Veeva Systems in April 2009. "Veeva" is derived from the Latin "viva," meaning "to live" — a nod to the life sciences mission.
The first product — Veeva CRM — was built on Salesforce's Force.com platform. This is the part of the story that nobody talks about.
Gassner had literally helped architect the platform. He understood it better than almost anyone outside Salesforce. So when he needed to get to market fast without burning capital on infrastructure, he used it. He became Salesforce's ISV (Independent Software Vendor) partner — Veeva CRM was listed on the Salesforce AppExchange.
The relationship was symbiotic and strange: Salesforce's own platform was enabling a company that would eventually outcompete Salesforce in pharma, charge Salesforce's customers to leave Salesforce's platform, and then — eighteen years later — cut Salesforce off entirely.
But that was far in the future. In 2007, the strategy made complete sense. Building on Force.com meant:
- No multi-tenant cloud infrastructure to build from scratch
- Instant credibility with enterprise IT teams that already trusted Salesforce
- All engineering resources focused on the pharma-specific layer
The risk was paying Salesforce a revenue share — reportedly 12–15% of Veeva's total revenue — forever. At $2+ billion in revenue, that's $250–300 million a year going to your former employer. A number that would eventually make the split inevitable.
Veeva did something unusual for enterprise SaaS: it refused to raise money until it didn't need it.
Gassner's philosophy: "Run a profitable lemonade stand." More formally: "Just run a profitable lemonade stand. Cash generating business is always going to be valuable to somebody. At some point, a business that's not cash generating is going to be valuable to nobody."
The company reached $45 million in annual revenue before seeking venture capital. The Series A, in June 2008 from Emergence Capital Partners, was just $4 million. Veeva raised a total of $7 million in venture funding before its IPO — and used only $3 million of it.
Emergence Capital's Gordon Ritter explicitly backed the "Industry Cloud" thesis — one of the earliest institutional bets that vertical SaaS was real.
The first major enterprise win was Pfizer. When a Pfizer executive asked why they should buy from a tiny company, Gassner's response was direct: "We're your only shot at greatness." He restated his conviction. Pfizer bought. That multimillion-dollar deal essentially funded continued product development without dilution.
October 16, 2013. Veeva goes public.
IPO price: $20 per share. The range had started at $12–$14, then moved to $16–$18, then finally $20 — each revision upward a signal of institutional demand that surprised the market.
First-day close: $37.16 — up 86% on the opening day.
Market cap at IPO price: $2.9 billion.
Market cap at close of Day 1: nearly $5 billion.
Veeva raised $217 million in the offering. For context, it had raised only $7 million in venture capital over six years to get there.
The headline in TechCrunch: "Veeva Systems' Life Science Cloud IPO Is A Hit, Raising $217M And Closing Up 85%"
The Pando headline the same day: "Four billion reasons why Veeva just proved verticals are the new hotness."
That day, "vertical SaaS" as an investment category was born. Gassner hadn't coined the term. He had just proved it worked — with a $5 billion company on Day 1 of trading.
The numbers that materialized over the following decade are extraordinary:
Compare this to Salesforce, which serves every industry on earth:
- Salesforce market cap (March 2026): ~$179 billion
- Veeva market cap (early 2026): ~$30–36 billion
Veeva is approximately 1/5 the size of Salesforce by market cap. Salesforce serves 150,000+ companies across every industry. Veeva serves ~1,900 companies in one vertical.
The valuation ratio is the argument for vertical SaaS in a single number.
In December 2022, Veeva announced it would not renew its Salesforce partnership when it expired in September 2025.
The migration: Veeva built its own proprietary CRM platform — Vault CRM — launched for general availability in April 2024. Built on Veeva's own Vault infrastructure. No Salesforce. No revenue share.
The transition runs through 2030. Most migrations happen 2026–2029.
The irony is not lost: a company founded by a Salesforce SVP, built on Salesforce's own platform, that achieved 80% market share in pharma CRM while paying Salesforce hundreds of millions per year... is now replacing Salesforce at every pharma company it serves.
Salesforce responded in June 2024 by launching a "Life Sciences Cloud" in partnership with IQVIA — its first serious move into the territory Veeva has owned for seventeen years.
On February 1, 2021, Veeva became the first publicly traded company in history to convert to a Delaware Public Benefit Corporation (PBC).
Delaware created the PBC legal structure in 2013. In the eight years before Veeva's conversion, no publicly traded company had used it. Veeva was the first. And at $35+ billion in market cap, the largest company of any kind to make the conversion.
What does it mean? As a traditional C-corp, a board's legal duty runs primarily to shareholders. As a PBC, Veeva's board is legally required to balance the interests of shareholders and a broader public benefit. The conversion isn't symbolic — it's in the corporate charter. It changes what directors are legally required to consider.
Veeva's stated public benefit purpose: "make the industries it serves more productive and create high-quality employment opportunities."
The shareholder vote: 99% in favor.
The source of the decision: Gassner himself. As Paul Shawah, Veeva's SVP of Commercial Strategy, explained: "PBCs did not exist when he founded the company, so Veeva became a traditional for-profit corporation focused on shareholders. Peter was never comfortable with that."
The conversion formalized what Veeva had always done: asked whether a decision was good for customers and employees alongside shareholders. The legal structure now mandates it.
Why does this matter? Institutional investors including BlackRock and State Street voted yes. ISS (the major proxy advisory firm) supported it. At a moment when "stakeholder capitalism" was a PR talking point for most companies, Veeva put it in its charter.
Veeva CRM was the origin. But Gassner's strategy was always to expand across the entire life sciences value chain — not just commercial operations, but research and development, clinical trials, regulatory submissions, quality management.
The Vault platform became the engine: a proprietary content management and data platform built specifically for life sciences workflows. Today it spans:
This is the move that separates Veeva from a CRM company. They're not selling software to pharma sales teams. They are building the operating system for how drugs get discovered, tested, approved, and marketed — globally.
Medidata (acquired by Dassault Systèmes in 2019 for $5.8 billion) had owned the clinical trial data space for years. Veeva is now competing directly with them, embedded in the same enterprise accounts that already run Veeva CRM.
1. It was almost called something else entirely.
Veeva was incorporated as "Verticals onDemand, Inc." — a name that suggests a company building for many verticals. It wasn't until 2009, two years in, that it became Veeva Systems. By then, the one-vertical thesis was already working.
2. The first four customers all said no.
When Gassner went to his first four potential pharma customers with his product concept, all four told him it was a bad idea. He signed them anyway — because he could tell from how they talked about their existing tools that they were emotionally detached from them. He listened to the signal under the words.
3. It reached $45M in revenue before taking a dollar of VC.
The company hit $45 million in annual recurring revenue before seeking outside investment. The Series A was $4 million. Total VC raised before a $4.4 billion IPO: $7 million. They used $3 million of it.
4. It was paying Salesforce ~$250–300M per year.
As a Salesforce ISV, Veeva paid roughly 12–15% of total revenue to Salesforce in hosting/platform fees. At $2B+ in revenue, that was hundreds of millions annually going to a company that was also their largest competitive threat. The moment Salesforce's non-compete clause expired in September 2025, Salesforce launched directly into pharma.
5. The founder was never comfortable being a C-corp.
Peter Gassner did not want to run a shareholder-only company. When Delaware's Public Benefit Corporation structure was created in 2013, he started planning the conversion. Eight years later, Veeva became the first publicly traded PBC in history — with 99% shareholder approval. The legal structure now requires the board to consider customers and employees alongside shareholders. Gassner calls this formalizing what they were always doing.
"Starting Veeva, I had the idea or vision you could make very industry-specific software in the cloud and it would be bigger than anyone would have thought. In 2007, most people thought that was incorrect." — Gassner
"When you start a company, you should try to do something that most people think is a bad idea because, otherwise, it's just too obvious." — Gassner
"You have to pick something that most people think is going to fail to be an outlier. Otherwise, by definition, you're picking something that most people think is going to work." — Gassner
"Run a profitable lemonade stand." — Gassner on capital efficiency
"You have to listen to what they feel, not what they say." — Gassner on early customer discovery
"We're your only shot at greatness." — Gassner to Pfizer executive who asked why they should buy from a tiny company
"PBCs did not exist when he founded the company, so Veeva became a traditional for-profit corporation focused on shareholders. Peter was never comfortable with that." — Paul Shawah, SVP Commercial Strategy
| Metric | Data |
|---|---|
| Founded | January 2007 (as Verticals onDemand) |
| Co-founders | Peter Gassner (ex-Salesforce SVP) + Matt Wallach (ex-Siebel) |
| Total VC raised before IPO | $7 million ($4M Series A from Emergence Capital, 2008) |
| Revenue before first VC | $45 million ARR |
| IPO date | October 16, 2013 |
| IPO price | $20/share |
| Day 1 close | $37.16/share (+86%) |
| IPO proceeds | $217 million |
| Market cap Day 1 | ~$5 billion |
| Current market cap | ~$30–36 billion (2026) |
| Salesforce market cap | ~$179 billion (March 2026) |
| Pharma CRM market share | ~80% |
| Top 20 pharma customers | 19 of 20 |
| FY2025 revenue | $2.747 billion |
| Free cash flow margin | ~45% |
| Net revenue retention | 120%+ |
| PBC conversion | February 1, 2021 (first public company ever) |
| Shareholder vote on PBC | 99% in favor |
| Salesforce partnership end | September 2025 |
| Vault CRM launch | April 2024 |
Angle 1 — The contrarian bet:
"Everyone building SaaS in 2007 was going horizontal. Salesforce for everyone. CRM for all industries. Peter Gassner did the opposite: one industry only, and his first four customers told him it was a bad idea. He became a $5B company on Day 1 of his IPO."
Angle 2 — Built on the platform it replaced:
"Veeva was built on Salesforce's own platform by the man who helped architect it. For 18 years, Veeva paid Salesforce 12–15% of revenue in platform fees — potentially hundreds of millions a year — while systematically replacing Salesforce CRM at every major pharma company. In 2025, the contract expired. Now they're competitors."
Angle 3 — $7M to $4.4B:
"Veeva hit $45M in ARR before taking outside money. Total VC raised before a $4.4B IPO: $7 million. The entire enterprise software world was raising hundreds of millions to scale. Gassner's philosophy: 'Run a profitable lemonade stand.' One of the most capital-efficient paths to a major tech IPO in history."
Angle 4 — The PBC conversion:
"In 2021, Veeva became the first publicly traded company in history to convert to a Public Benefit Corporation. 99% of shareholders voted yes. The legal charter now requires Veeva's board to consider customers and employees, not just shareholders. The founder's explanation: he was never comfortable with the other structure. He'd been waiting since 2013 for the legal vehicle to exist."
Angle 5 — The valuation ratio:
"Salesforce serves every industry on earth: $179B market cap. Veeva serves one industry only — pharma and life sciences: $30–36B market cap. Veeva is 1/5 the size of Salesforce by market cap, serving roughly 1/100th of its customer base. That's the argument for vertical SaaS in a single ratio."
